ZEB1 and prostate carcinoma: Remarkably silibinin was able to reverse epithelial-to-mesenchymal transition (EMT) in metastatic prostate cancer cells by down-regulating the two major EMT regulators, ZEB1 and SLUG transcription factors [50], while its role in inhibiting STAT3 signaling is well documented [51].